Danaher Corporation (DHR) Stock Price & Analysis
Danaher Corporation (DHR) closed at USD 229.75 on Thursday, October 22, 2026, down 1.76% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 233.86; the Oct 22, 2026 session ranged USD 228.17–238.13 on volume of 7,066,734 shares. Market capitalization is $161.51B, with a 52-week range of USD 160.93–242.8 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DHR.md
Latest Earnings Results (DHR)
Danaher Corporation (DHR) reported Q3 2026 results on Oct 20, 2026, 5:43:14 PM ET: adjusted EPS $2.11 vs. estimate $1.92 (beat), revenue $6.60B vs. estimate $6.56B (beat). Guidance: For full year 2026, the Company is increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.57 to $8.62. Source: SEC 8-K filing. Read the SEC filing.
| Fiscal period | EPS (reported) | Revenue | Released | Source |
|---|---|---|---|---|
| Q3 2026 | $2.11 (adjusted (non-GAAP) diluted) | $6.60B | Oct 20, 2026, 5:43:14 PM ET | SEC 8-K filing |
Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.
Key facts (DHR)
- Last four reported quarters (through Sep 25, 2026): revenue $25.6B, net income $4.33B (16.9% margin), free cash flow $5.73B (SEC filings).
- Valuation: P/E 37.3x (avg 41.6x at the last 3 fiscal year-ends), EV/EBITDA 30.3x, net debt $20.8B.
- 12 of 80 tracked superinvestors hold DHR (13F, Q2 2026 (1 investor on Q3 2026, filed early)): 2 new, 6 added, 0 reduced, 4 unchanged.
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $13.0M; 2 not under a Rule 10b5-1 plan ($13.0M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.04 on a 1–5 scale) (24 analysts), mean target USD 258.86 (range 205–310).
- Total return with dividends: 1Y +3.9% vs S&P 500 +14.9%; 5Y -15.2% vs S&P 500 +80.3%.
- Next earnings: 2026-10-21, EPS estimate USD 2.49, revenue estimate $7.49B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DHR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $24.8B | $26.6B | $23.9B | $23.9B | $24.6B | $25.6B |
| Gross profit | $15.2B | $16.2B | $14.0B | $14.2B | $14.5B | — |
| Operating income | $6.38B | $7.54B | $5.20B | $4.86B | $4.69B | $5.22B |
| Net income | $6.43B | $7.21B | $4.76B | $3.90B | $3.61B | $4.33B |
| EPS (diluted) | $8.61 | $9.66 | $6.38 | $5.29 | $5.05 | — |
| Free cash flow | $7.12B | $7.40B | $5.78B | $5.30B | $5.26B | $5.73B |
| Gross margin | 61.4% | 60.8% | 58.7% | 59.5% | 59.1% | — |
| Operating margin | 25.7% | 28.3% | 21.8% | 20.4% | 19.1% | 20.4% |
| Net margin | 25.9% | 27.1% | 19.9% | 16.3% | 14.7% | 16.9% |
| Revenue growth | +11.3% | +7.4% | -10.3% | -0.1% | +2.9% | — |
| Cash + short-term investments | $2.59B | $6.00B | $5.86B | $2.08B | $4.62B | — |
| Total debt | $22.2B | $19.7B | $18.4B | $16.0B | $18.4B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 25, 2026) (DHR)
P/E 37.3x · P/S 6.3x · EV/EBITDA 30.3x · EV/Sales 7.1x · P/FCF 28.2x · P/B 3.0x · FCF yield 3.55% · Earnings yield 2.68% · Dividend yield (paid, TTM) 0.63% · Buyback yield (TTM) 0.55% · Net debt $20.8B · EV $182B
P/E at fiscal year-ends: Dec 2025 45.4x, Dec 2024 43.4x, Dec 2023 36.1x.
Superinvestors (SEC 13F-HR, Q2 2026) (DHR)
12 of 80 tracked investors hold DHR (1 investor on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Pat Dorsey | Dorsey Asset Management | 7.64% | $119M | Added +7.9% | Q2 2026 |
| Wallace Weitz | Weitz Investment Management | 6.46% | $93.2M | Added +2.5% | Q2 2026 |
| Daniel Loeb | Third Point | 2.22% | $103M | Added +2.9% | Q2 2026 |
| Van Den Berg Management I | 1.73% | $8.2M | Added +18.8% | Q2 2026 | |
| First Pacific Advisors | 1.35% | $108M | New position | Q2 2026 | |
| Chase Coleman | Tiger Global Management | 0.36% | $86.9M | New position | Q2 2026 |
| Bill Gates | Gates Foundation Trust | 0.21% | $71.0M | Unchanged | Q2 2026 |
| Torray Funds | 0.05% | $356K | Unchanged | Q2 2026 | |
| Dodge & Cox Funds | Dodge & Cox | 0.03% | $49.0M | Added +1462.5% | Q2 2026 |
| David Katz | Matrix Asset Advisors | 0.03% | $372K | Unchanged | Q3 2026 |
| Bill Nygren | Oakmark Funds | <0.01% | $350K | Unchanged | Q2 2026 |
| Mairs & Power | Mairs & Power Funds | <0.01% | $218K | Added +0.6% | Q2 2026 |
Insider sales (SEC Form 4, open-market, last ~7 months) (DHR)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-21 | Blair Rainer | President & CEO | 58,255 | $12.7M | 60.5% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-05-01 | Spoon Alan G | Director | 1,358 | $237K | 1% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (DHR)
Consensus Buy (mean 2.04 on a 1–5 scale), 24 analysts; mean target USD 258.86 (low 205, high 310).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Citigroup | Target raised | Buy | $230 → $270 |
| 2026-10-22 | Barclays | Target raised | Overweight | $255 → $260 |
| 2026-10-22 | JP Morgan | Target raised | Overweight | $250 → $270 |
| 2026-10-22 | TD Cowen | Target raised | Buy | $255 → $270 |
| 2026-10-22 | Stifel | Target raised | Buy | $220 → $260 |
| 2026-10-22 | Baird | Target raised | Outperform | $246 → $254 |
| 2026-10-13 | Morgan Stanley | Target raised | Overweight | $220 → $240 |
| 2026-10-13 | TD Cowen | Target raised | Buy | $236 → $255 |
| 2026-10-07 | Barclays | Target raised | Overweight | $230 → $255 |
| 2026-10-05 | RBC Capital | Target raised | Outperform | $215 → $250 |
| 2026-10-01 | Guggenheim | Target raised | Buy | $200 → $250 |
| 2026-07-22 | Wells Fargo | Target lowered | Equal-Weight | $212 → $195 |
Total return (dividends reinvested) (DHR)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +3.9% | -15.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +3.9% | -3.2% |
| Volatility (annualized) | 30.3% | 29.1% |
| Max drawdown | -33.0% (Jan 2026→May 2026) | -43.3% (Dec 2021→May 2026) |
DHR revenue by business segment (quarter ended Sep 25, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Diagnostics | $2.88B | 44.0% | +17.0% |
| Life Sciences | $1.86B | 28.5% | +4.1% |
| Biotechnology | $1.81B | 27.6% | +0.5% |
| Total revenue | $6.55B | 100% | — |
DHR revenue by product line (quarter ended Sep 25, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Recurring revenue | $1.58B | 24.2% | -0.4% |
| Nonrecurring revenue | $223.0M | 3.4% | +7.2% |
| Total revenue | $6.55B | 100% | — |
DHR revenue by region (quarter ended Sep 25, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| North America | $2.74B | 41.8% | +6.2% |
| High-growth markets | $2.03B | 30.9% | +15.0% |
| Western Europe | $1.49B | 22.7% | +6.7% |
| Other developed markets | $298.0M | 4.5% | -5.7% |
| Total revenue | $6.55B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
DHR suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Veralto Corp (VLTO) | “In connection with the Veralto Separation, Danaher and Veralto entered into various agreements to effect the Veralto Separation and provide a framework for their relationship after the Veralto Separation, including a separation and distribution agreement, transition services agreement, an employee matters agreement, a tax matters agreement, an intellectual property matters agreement and a DANAHER BUSINESS SYSTEM (…” |
Quoted from the company's 10-K filed Feb 24, 2026.
DHR company outlook (results filed Oct 21, 2026)
- “For the fourth quarter 2026, the Company anticipates that non-GAAP core revenue excluding respiratory revenue will increase in the 4.0% to 5.0% range year-over-year.”
- “We expect respiratory revenue to be an approximately 150 basis point headwind, resulting in core revenue growth of approximately 3.0%.”
- “For full year 2026, the Company is increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.57 to $8.62 versus previous guidance of $8.45 to $8.60.”
- “Conference Call and Webcast Information Danaher will discuss its third quarter results and financial guidance for the fourth quarter and full year 2026, including as applicable key assumptions with respect thereto, during its investor conference call today starting at 8:00 a.m.”
Quoted word-for-word from the SEC 8-K results press release.
DHR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $2.49 | $2.58 | -3.6% | $7.49B | 20 |
| Next quarter (ends Mar 2027) | $2.24 | $2.23 | +0.2% | $6.64B | 13 |
| Current fiscal year (ends Dec 2026) | $8.57 | $8.51 | +0.8% | $26.26B | 24 |
| Next fiscal year (ends Dec 2027) | $9.33 | $9.26 | +0.7% | $28.33B | 24 |
DHR options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 35.2% | ±4.2% |
| Nov 6, 2026 | 14 | 33.9% | ±5.5% |
| Nov 13, 2026 | 21 | 32.4% | ±6.4% |
| Nov 20, 2026 | 28 | 31.5% | ±7.1% |
| Nov 27, 2026 | 35 | 30.3% | ±7.6% |
| Dec 4, 2026 | 42 | 30.9% | ±8.5% |
| Dec 18, 2026 | 56 | 31.3% | ±9.9% |
| Jan 15, 2027 | 84 | 31.1% | ±12.0% |
30-day implied volatility 31.8% vs 30.1% realized over the last 30 trading days. Put/call ratio (volume) 0.92. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 229.75 |
|---|---|
| Change | ▼ 1.76% (down) |
| Previous Close | USD 233.86 |
| Open | USD 233.8 |
| Day Range | USD 228.17 – 238.13 |
| 52-Week Range | USD 160.93 – 242.8 |
| Volume | 7,066,734 shares |
| Market Cap | $161.51B |
| Exchange | NYQ |
Technical Analysis (DHR)
Nexqual's technical model rates DHR "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.01 (neutral) |
| vs SMA50 | Above (USD 215.6) |
| MACD | 4.22 (positive) |
Analyst Ratings (DHR)
Wall Street analysts rate DHR "Buy" based on 24 analysts, with a mean price target of USD 258.86 (range USD 205–310), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 24 |
| Mean Target | USD 258.86 |
| High Target | USD 310 |
| Low Target | USD 205 |
| Buy / Hold / Sell | 20 / 4 / 0 |
Earnings (DHR)
| Next Earnings Date | 2026-10-21 |
|---|---|
| EPS Estimate | USD 2.49 |
| Revenue Estimate | $7.49B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 2.11 vs est 1.92 ▲ beat |
| 2026-06-30 | USD 1.94 vs est 1.84 ▲ beat |
| 2026-03-31 | USD 2.06 vs est 1.94 ▲ beat |
| 2025-12-31 | USD 2.23 vs est 2.19 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (DHR)
| Total Revenue | $25.61B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.30% |
| Gross Margin | +58.71% |
| Operating Margin | +19.00% |
| Profit Margin | +16.91% |
| ROE | +8.19% |
| Debt / Equity | 0.49 |
| Current Ratio | 1.63 |
| Total Cash | $5.68B |
| Total Debt | $26.48B |
| Free Cash Flow (last four quarters to Sep 2026, SEC 10-Q / 10-K) | $5.73B (22.4% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (DHR)
Nexqual rates Danaher Corporation's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Mixed — Revenue +2.9% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 59%, operating 19% (last 12 months) |
| Balance Sheet | Solid — $5.68B cash and investments vs $26.5B debt (Sep 2026, SEC) |
| Cash Flow | Strong — FCF $5.73B (last 4 quarters to Sep 2026, SEC), 22% margin |
| Efficiency | Mixed — ROE 8%, ROA 4.3% |
Ownership (DHR)
| Insider Ownership | +10.81% |
|---|---|
| Institutional Ownership | +84.10% |
| Shares Outstanding | 702.99M |
| Float | 626.27M |
| Short % of Float | +1.43% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (DHR)
Danaher Corporation is led by Julie Sawyer Montgomery, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.
| President, CEO & Director | Julie Sawyer Montgomery |
|---|---|
| Co-Founder & Chairman | Steven M. Rales |
| Co-Founder & Director | Mitchell P. Rales |
| Executive Vice President | Matthew R. McGrew |
| Executive VP & CFO | Matthew E. Gugino C.F.A. |
Major Backers & Investors (DHR)
Notable institutional backers of Danaher Corporation include FMR, LLC, Wellington Management, Capital International Investors, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 4.2% |
| Wellington Management | 2.32% |
| Capital International Investors | 2.21% |
| Fidelity | 2.2% |
| JPMorgan | 1.73% |
| Price (T.Rowe) Associates Inc | 1.63% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.91% |
| BlackRock | 7.84% |
| State Street | 4.05% |
| Geode Capital | 2.03% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From Danaher Corporation's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- The genomic medicines business is a leading provider of custom nucleic acid products for the life sciences industry, primarily through the manufacture of custom DNA and RNA oligonucleotides and gene fragments utilizing a proprietary manufacturing ecosystem.
- Department of Health and Human Services ("HHS"), including the Centers for Medicare & Medicaid Services ("CMS"), as well as comparable state and non-U.S. agencies responsible for reimbursement and regulation of healthcare goods and services, including laws and regulations related to kickbacks, false claims, self-referrals and healthcare fraud.
- Danaher strives to create shareholder value primarily through three strategic priorities: •strengthening our competitive advantage through consistent application of DBS tools and culture; •enhancing our portfolio in attractive science and technology markets through strategic capital allocation; and •consistently attracting and retaining exceptional talent.
Partnerships
- Regulatory requirements in the United Kingdom ("UK") are also changing as a result of Brexit (the UK's withdrawal from the EU), and regulatory requirements in Switzerland are changing as a result of the country's withdrawal from its Mutual Recognition Agreement with the EU Commission.
Legal & Regulatory Risks (Item 1A, quoted)
- Our business and financial statements can be impaired by improper conduct by any of our employees, agents or business partners.
- Our businesses are subject to extensive regulation; failure to comply with those regulations could adversely affect our business and financial statements.
- We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in the course of our business that can adversely affect our business and financial statements.
- Government authorities have in the past and may in the future conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc | USD 676.54 | ▼ 2.52% |
| NTRA | Natera, Inc. | USD 401.37 | ▼ 2.91% |
| A | Agilent Technologies, Inc. | USD 173.89 | ▼ 2.17% |
| IQV | IQVIA Holdings, Inc. | USD 278.32 | ▲ 0.61% |
| WAT | Waters Corporation | USD 455.59 | ▼ 0.41% |
| IDXX | IDEXX Laboratories, Inc. | USD 566.76 | ▲ 2.4% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt